Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Lipocine (LPCN) over the last 11 years, with Q3 2025 value amounting to $5870.0.

  • Lipocine's Gains from Investment Securities fell 9795.1% to $5870.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$16754.0, marking a year-over-year decrease of 10584.81%. This contributed to the annual value of $335258.0 for FY2024, which is 2784.05% up from last year.
  • Lipocine's Gains from Investment Securities amounted to $5870.0 in Q3 2025, which was down 9795.1% from -$6764.0 recorded in Q2 2025.
  • Lipocine's Gains from Investment Securities' 5-year high stood at $4.5 million during Q1 2023, with a 5-year trough of -$34243.0 in Q4 2022.
  • Its 5-year average for Gains from Investment Securities is $1.2 million, with a median of $286484.0 in 2024.
  • Per our database at Business Quant, Lipocine's Gains from Investment Securities plummeted by 12278.04% in 2022 and then soared by 108162.99% in 2023.
  • Lipocine's Gains from Investment Securities (Quarter) stood at $150318.0 in 2021, then tumbled by 122.78% to -$34243.0 in 2022, then surged by 64.16% to -$12274.0 in 2023, then soared by 70.78% to -$3586.0 in 2024, then skyrocketed by 263.69% to $5870.0 in 2025.
  • Its last three reported values are $5870.0 in Q3 2025, -$6764.0 for Q2 2025, and $349616.0 during Q1 2025.